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A B S T R A C T
Question: In people with nerve-related leg pain, does adding neurodynamic treatment to advice to
remain active improve leg pain, disability, low back pain, function, global perceived effect and location of
symptoms [41_TD$DIFF]? Design: Randomised trial with concealed allocation and intention-to-treat analysis.
Participants: Sixty participants with nerve-related leg pain recruited from the community. Interven-
tions: The experimental group received four sessions of neurodynamic treatment. Both groups received
advice to remain active.Outcomemeasures: Leg pain and low back pain ( [42_TD$DIFF]0, none [43_TD$DIFF], to [44_TD$DIFF]10, worst), Oswestry
Disability Index ( [42_TD$DIFF]0, none [43_TD$DIFF], to [45_TD$DIFF]100, worst), Patient-Speciﬁc Functional Scale ([42_TD$DIFF]0, unable to perform [46_TD$DIFF], to [47_TD$DIFF]30,
able to perform), global perceived effect (–5 to 5) and location of symptoms were measured at 2 and
4 weeks after randomisation. Continuous outcomes were analysed by linear mixed models. Location of
symptoms was assessed by relative risk (95% CI). Results: At 2 weeks, the experimental group did not
have signiﬁcantly greater improvement [48_TD$DIFF]than the control group in leg pain (MD –1.1, 95% CI –2.3 to 0.1) or
disability (MD –3.3, 95% CI –9.6 to 2.9). At 4 weeks, the experimental group experienced a signiﬁcantly
greater reduction in leg pain (MD –2.4, 95% CI –3.6 to –1.2) and low back pain (MD –1.5, 95% CI –2.8 to –
0.2). The experimental group also improved signiﬁcantly more in function at 2 weeks (MD 5.2, 95% CI
2.2 to 8.2) and 4 weeks (MD 4.7, 95% CI 1.7 to 7.8), as well as global perceived effect at 2 weeks (MD 2.5,
95% CI 1.6 to 3.5) and 4 weeks (MD 2.9, 95% CI 1.9 to 3.9). No signiﬁcant between-group differences
occurred in disability at 4 weeks and location of symptoms. Conclusion: Adding neurodynamic
treatment to advice to remain active did not improve leg pain and disability at 2 weeks. Trial
registration:NCT01954199. [Ferreira [49_TD$DIFF]G, Stieven [50_TD$DIFF] , Araujo [51_TD$DIFF] ,WiebuschM, Rosa [52_TD$DIFF]C, [11_TD$DIFF] Plentz R, et al. (2016)
Neurodynamic treatment did not improve pain and disability at two weeks in patients with chronic
nerve-related leg pain: a randomised trial. Journal of Physiotherapy 62: 197–202]
 2016 Australian Physiotherapy Association. Published by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Low back pain is a highly prevalent and disabling condition that
represents the major cause of years lived with disability in both
developed and developing countries.1 Among the wide array of
clinical presentations, the prevalence of radiating leg pain can be
up to 60% in primary care.2 In addition, people with low back pain
and radiating leg pain present higher levels of work-related
disability, lower levels of quality of life and a poorer prognosis than
those with low back pain only.3
To date, there is no consensus on the most appropriate
management strategy for people with nerve-related leg pain. A
recent network meta-analysis found that a range of widely used
conservative treatments, such as acupuncture, exercise therapy,
traction, passive physiotherapy modalities (eg, ultrasound and
transcutaneous electrical nerve stimulation), and advice/education
alone, were not effective in reducing leg pain compared with no
treatment.4[53_TD$DIFF] espite the high risk of bias of several included studies,http://dx.doi.org/10.1016/j.jphys.2016.08.007
1836-9553/ 2016 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).aswell as moderate-to-high levels of between-study heterogeneity,
this networkmeta-analysis provided evidence that commonly used
conservative interventions were not capable of altering the natural
history of leg pain. Therefore, other conservative treatment
strategies should be investigated in this population as a research
priority, given the cost-effectiveness of stepped-care approaches
compared with direct referral for surgery.4
One conservative intervention that warrants further investiga-
tion is neurodynamic treatment. This approach has been consid-
ered to be effective for patients with signs of nerve
mechanosensitivity,5 which can be clinically assessed by provoca-
tive tests that challenge the ability of the nerve tissue to tolerate
tension.6 In neurodynamic treatment, speciﬁc positions, and active
and passive movements of the lumbar spine and legs are used to
mobilise structures around the nervous system and the nervous
system itself.7
Despite the plausible biological rationale of this treatment
approach,8–10 little is known about its effects on patient-important.V. This is an open access article under the CC BY-NC-ND license (http://
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and two randomised trials12,13 have investigated the effects of
neurodynamic treatment on nerve-related leg pain. However, case
series are at high risk of bias and both trials enrolled participants
likely to represent a mixed sample of acute, subacute and chronic
pain, which may have inﬂuenced the outcomes due to differences
in the expected prognosis of leg pain and disability. Moreover, the
paucity of high-quality studies assessing the effects of this
treatment approach was highlighted by a clinical practice
guideline that recommended neurodynamic treatment for patients
with chronic nerve-related leg pain based only on weak
evidence.14 As such, there is a need for a randomised trial to
assess the effects of neurodynamic treatment in patients with
chronic nerve-related leg pain.
Therefore, the research questions for this randomised trial
were:1. In people with nerve-related leg pain, does adding neurody-
namic treatment to advice to remain active improve leg pain and
disability?2. Does it improve low back pain, function and global perceived




This study was a prospectively registered, parallel-group,
randomised, controlled trial. This trial was reported according to
the recommendations of the Consolidated Standards of Reporting
Trials (CONSORT) statement.15 The study protocol was published
previously.16
At baseline, the presence of neuropathic pain was assessed by
the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
score, in which a score  12 indicates the presence of neuropathic
pain.17 A neurological examination, comprising manual muscle
strength testing of the lower limbs, patellar and Achilles reﬂexes
and sensation, was carried out and participants with at least one
positive neurological ﬁnding were classiﬁed as having nerve root
compromise. Fear-avoidance beliefs were assessed using the Fear-
Avoidance Beliefs Questionnaire (FABQ), and pain catastrophising
was evaluated using the Pain Catastrophising Scale (PCS).
Medication intake was also recorded.
Following baseline assessment, participants were randomly
assigned to neurodynamic treatment or advice to remain active.
Randomisation followed a 1:1 ratio and was stratiﬁed by current
leg pain intensity in two strata (pain ranging from 3 to 6, and pain
ranging from 7 to 10 on a scale from 0, no pain, to 10, worst
imaginable pain). Within each stratum, allocations were arranged
in blocks of six, randomised by shufﬂing, and sealed in sequentially
numbered, opaque envelopes by a researcher not involved in
assessment or treatment provision. Each envelope was opened
only after the enrolled participant completed all baseline
assessments.18 [14_TD$DIFF]
Participants, therapists and centres
Participants were recruited from the community through
advertisements in local newspapers and social media between
March 2015 andMarch 2016. Although recruitment from secondary
healthcare facilities was planned and described in the study
protocol,16 no participant was recruited from such facilities due to
lack of referrals. Adults aged 18 to 80 years with chronic unilateral
nerve-related leg pain (ie, leg pain for at least 12 weeks) radiating
below the gluteal fold were included. Participants had to report a
leg pain intensity of at least 3 on an 11-point [57_TD$DIFF]numerical pain rating
scale[58_TD$DIFF] (NPRS), and their leg symptoms had to be reproduced by theslump test and changed by structural differentiation (ie, releasing of
cervical ﬂexion or ankle dorsiﬂexion).19[56_TD$DIFF] Current low back pain was
not a necessary criterion for an individual to be included.
Participants were excluded if they had signs of cauda equina
syndrome, bilateral leg pain, positive crossed Lase`gue sign, previous
surgery in the lumbar spine or in the symptomatic leg, inﬂamma-
tory arthropathies, fractures or malignancy. Those with workers
compensation claims or on physiotherapy treatment at the time of
baseline assessment were also excluded. Participants who met all
eligibility criteria and provided informed consent entered the trial.
A physiotherapist with 2 years of clinical experience who
attended a 40-hour course of management of neuromusculoske-
letal disorders with neurodynamic techniques provided treatment
to all participants. All treatment sessions were provided in a
private physiotherapy practice located in Porto Alegre, Brazil.
Intervention
Participants in both groups received advice to remain active,
which was delivered in a face-to-face format. The advice focused
on two aspects: that prolonged rest, avoidance of daily-life
activities and excessive muscle bracing during movement would
have harmful effects; and that light activities and movements
would be beneﬁcial for pain. At the baseline assessment,
participants were advised to maintain their usual activities. In
addition to this advice, participants randomised to the experimen-
tal group received the neurodynamic treatment and [59_TD$DIFF]a [60_TD$DIFF]home
[61_TD$DIFF]exercise [62_TD$DIFF]program.
Neurodynamic treatment consisted of passive or active move-
ments, which aimed to desensitise the overly sensitised nervous
system by restoring its ability to tolerate external forces such as
movement and compression.20 Participants received four treat-
ment sessions over 2 weeks (two sessions per week) with each
treatment session lasting up to 25 minutes. On the ﬁrst appoint-
ment, participants were informed that nerve sensitisation was
playing a role in their leg symptoms and that the treatment goal
was to desensitise it. This educational component was applied in a
previous trial.21
Participants received grade III lumbar foramen opening
mobilisations and neurodynamic sliders. Reproduction of the
participant’s symptoms was not allowed during the treatment, but
a mild pull sensation was tolerated. The lumbar foramen-opening
mobilisation was performed for two sets of 30 oscillations at
0.5 Hz, with the participants in side lying (painful side uppermost)
and hips ﬂexed. If the participant’s symptoms did not worsen after
two sets of mobilisation, both legs were draped over the side of the
table in order to increase the foramen size, and one additional set
of 30 oscillations was performed.
For the neurodynamic sliders, participants were initially
positioned in side lying (painful side uppermost) and a combina-
tion of hip and knee ﬂexion followed by hip and knee extension
was performed for two sets of 30 repetitions. If symptoms did not
worsen, a progression was added: the participants executed one
set of 30 repetitions of an active sliding technique in slump sitting,
which combined neck ﬂexion and knee ﬂexionwith neck extension
and knee extension. It has been shown that this exercise produces a
great amount of nerve excursion.6 During the active sliding
technique in slump sitting, the participant was instructed to
extend the knee up to the onset of symptoms.
The lumbar foramen opening techniquewas designed to reduce
pressure over the sensitised nervous system.22 The sliding
techniques were implemented with [64_TD$DIFF]the [65_TD$DIFF]aim of generating nerve
excursion[15_TD$DIFF] (elongation of the nerve bed at one joint is simulta-
neously counterbalanced by a reduction in the length of the nerve
bed at an adjacent joint). Neurodynamic sliding may reduce
intraneural oedema and venous congestion.5 [63_TD$DIFF] Furthermore, apart
frommechanical effects, neurophysiological effects have also been
described, such as the ability to inhibit temporal summation,
reﬂecting the ability of neurodynamic techniques to decrease
hyperexcitability of the dorsal horn.23 A video demonstration of
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Appendix 1).The intervention was applied following standardised algo-
rithms of progression, which means that the intervention was not
tailored to each participant’s symptoms (eg, the neurodynamic
sliders were not biased to the tibial or peroneal nerves).16
Nevertheless, a similar treatment protocol was shown to be
effective for patients with back-related leg pain with peripheral
nerve sensitisation.5 A treatment session was discontinued if a
participant reported an increase in leg pain ( 2 points on pain
rating scale), numbness or tingling.
The home exercise program involved one sliding (active sliding
in slump sitting) and one tensioning technique (active knee
extension in supine). Each exercise was performed for one set of
10 repetitions twice a day during the treatment period and was
standardised across participants. Participants were advised to
perform the exercises in a painless way. A self-reported exercise
log veriﬁed compliance. At the end of the treatment, home
exerciseswere no longermonitored, and the decision ofwhether to
continue or not was at the discretion of the participants. Neither
participants nor therapists were blinded to allocation.
Outcome measures
Baseline assessment was performed before randomisation and
investigators blinded to treatment allocation collected the follow-
up measures. If a participant could not attend the follow-up
sessions, data were collected over the telephone or a standardised
form was sent by email.
The primary outcomes were leg pain and disability measured
2 weeks after randomisation. The [67_TD$DIFF]NPRS[18_TD$DIFF], a scale from 0 ‘no pain’ to
10 ‘worst possible pain’, was used to assess leg pain. At each
assessment point, participants were asked to rate their average leg
pain intensity over the preceding 24 hours. A 2-point reduction in
NPRS was considered clinically relevant.24 [66_TD$DIFF] Disability was assessed
by the Brazilian version of the Oswestry Disability Index 2.0, for
which theminimum clinically important difference is 10 points on
the 0-to-100 scale.24 When these two outcomes (leg pain and
disability) were re-measured 4 weeks after randomisation, they
were considered secondary outcomes. The other secondary out-
comes were all measured at 2 and 4 weeks after randomisation.
These other secondary outcomes included low back pain intensity
(measured using the NPRS)[68_TD$DIFF], function (measured using the Patient-
Speciﬁc Functional Scale)[68_TD$DIFF],25 [19_TD$DIFF] location of symptoms[68_TD$DIFF],26 and global
perceived effect.27
Data analysis
Sample size was determined a priori.16 Enrolment of 60 parti-
cipants ensured that this trial was powered to detect a difference of
1.6 points in leg pain severity (with SD of 2.4 and 2.1) with 80%
power, a two-tailed alpha of 5% and an expected dropout rate of
20%. This sample size also had 80% power to detect a difference of
9 points (SD 12) on the 100-point Oswestry Disability Index.Data normality was checked by visual inspection of histograms,
which revealed a normal distribution for all data, except for
duration of symptoms. Descriptive statistics were presented for
each treatment group. Normally distributed, continuous variables
were summarised with means and SDs, whereas duration of
symptoms was reported with medians and ranges. Categorical or
dichotomous data were summarised with frequencies.
A repeated-measures linear mixed model, including terms for
participant, group, time and group by time interaction, was used to
assess the effects of treatment on leg pain, disability, lowback pain,
function and global perceived effect at 2 and 4 weeks. Repeated
measuresweremodelled using a Toeplitz covariance structure. The
model was adjusted for the presence of nerve root compromise.16
Mean scores, SDs and adjusted between-group differences (95%
CIs) were calculated for all outcomes across all time points. The
linear mixed model accounts for the dependency of the repeated
measures taken from each participant through time and handles
missing data without the need for imputation procedures. Data
were analysed following the intention-to-treat principle; that is,
participants were analysed according to their original group
allocation, regardless of treatment received after randomisation.
For location of symptoms, scores at each follow-upwere compared
against baseline values and coded as ‘centralised’ if the most distal
location of the pain moved towards the lumbar spine (eg, if pain
moved from 5 [leg] to 4 [thigh]), or ‘non-centralised’ if the most
distal location of the pain moved towards the feet or did not
change. Missing values were imputed using logistic regression and
the relative risk of pain (95% CI) centralisation was calculated. All
statistical tests were two-tailed and a p-value of < 0.05 was
considered statistically signiﬁcant.
Results
Flow of participants, therapists and centres through the study
From March 2015 to March 2016, 158 patients were recruited
and 60were eligible to be included in the study. In each group, two
participants were lost to follow-up up at Week 2 (93% follow-up)
and another one could not be followed up at Week 4 (90% follow-
up). The ﬂow of participants, reasons for ineligibility, and loss to
follow-up are detailed in Figure 1. Overall, most of the participants
were women with moderate levels of disability, low back pain and
leg pain. Baseline demographic and clinical characteristics of
enrolled participants are displayed in Table 1.
Adherence to the study protocol
All participants received the intervention to which they were
initially allocated. Participants in the neurodynamic treatment
group received a mean of 3.7 (1.0) sessions during the 2-week
intervention period. Home exercise compliance was 85%. No
adverse effects were observed during sessions. One participant
(2%) reported an adverse effect following home exercises – it
subsided within 24 hours. This participant performed vigorous
hamstring stretching instead of the oriented sliding and tensioning
techniques. Two participants (3%) reported co-interventions (one
participant in the experimental group sought chiropractic treat-
ment and one participant in the control group reported having
consulted a physiotherapist).
Effects of the intervention
There was no effect of neurodynamic treatment on leg pain
intensity at 2 weeks (MD –[70_TD$DIFF]1.1, 95% CI –2.3 to 0.1), but a signiﬁcant
effect on leg pain intensity was observed at 4 weeks (MD –[71_TD$DIFF]2.4, 95%
CI –3.6 to –1.2). There was no signiﬁcant effect of treatment on
disability at 2weeks (MD –[72_TD$DIFF]3.3, 95% CI –9.6 to 2.9) and 4weeks (MD
–[73_TD$DIFF]5.0, 95% CI –11.0 to 1.1), as presented in Table 2.
[(Figure_1)TD$FIG]
Figure 1. Design and ﬂow of participants through the trial.
Table 1
Baseline characteristics of the participants.
Characteristic Exp (n=30) Con (n=30)
Age (yr), mean (SD) 43.9 (14.5) 40.3 (12.9)
Gender, n female (%) 22 (77) 23 (73)
BMI (kg/m2), mean (SD) 26.8 (4.2) 27.3 (4.6)
Education, n (%)
elementary degree 2 (7) 3 (10)
high school 12 (40) 14 (47)
university 16 (53) 13 (43)
Smoker, n (%) 5 (17) 3 (10)
Duration of leg symptoms (yr),
median (range)
5.8 (0.25 to 50) 2.0 (0.25 to 20)
Use of medication, n (%)
NSAID 9 (30) 12 (40)
muscle relaxants 8 (27) 6 (20)
opioid 2 (7) 0 (0)
gabapentin 1 (3) 0 (0)
antidepressants 1 (3) 0 (0)
Nerve root compromise, n (%) 19 (63) 14 (47)
LANSS score (0 to 24), mean (SD) 11 (5) 12 (4)
Neuropathic pain, n (%) 11 (36) 15 (50)
FABQ, mean (SD)
Physical Activity domain (0 to 24) 15 (6) 14 (5)
Work domain (0 to 24) 15 (9) 18 (10)
PCS (0 to 52), mean (SD) 26 (10) 29 (10)
Low back pain 24 h (0 to 10), mean (SD) 5.5 (2.3) 5.1 (2.5)
Leg pain 24 h (0 to 10), mean (SD) 6.1 (1.6) 6.1 (1.9)
ODI (0 to 100), mean (SD) 27 (8) 29 (15)
PSFS (0 to 30), mean (SD) 14 (5) 15 (6)
Location of symptoms, n (%)
thigh 10 (33) 10 (33)
leg 12 (40) 10 (33)
foot 8 (27) 10 (33)
Con= control group=advice to remain active, Exp=experimental group=neur-
odynamic treatment, FABQ=Fear-Avoidance Beliefs Questionnaire, LANSS=Leeds
Assessment of Neuropathic Symptoms and Signs, NSAID=non-steroidal anti-
inﬂammatory drugs, ODI =Oswestry Disability Index, PCS=Pain Catastrophising
Scale, PSFS =Patient-[27_TD$DIFF]Speciﬁc Functional Scale [28_TD$DIFF].
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on low back pain intensity at 2 weeks (MD –[74_TD$DIFF]0.9, 95% CI –2.2 to 0.3),
but a signiﬁcant reduction favouring neurodynamic treatment
occurred at 4 weeks (MD –1.5, 95% CI –2.8 to –0.2). There was a
signiﬁcant effect of treatment on function at 2 weeks (MD [75_TD$DIFF] .2, 95%
CI [76_TD$DIFF]2.2 to [77_TD$DIFF]8.2) and 4 weeks (MD [78_TD$DIFF]4.7, 95% CI 1.7 to 7.8), as presented
in Table 2. Likewise, global perceived effect improved in favour of
neurodynamic treatment at 2weeks (MD [79_TD$DIFF]2.5, 95% CI 1.6 to 3.5) and
4 weeks (MD [80_TD$DIFF]2.9, 95% CI 1.9 to 3.9), as presented in Table 3.
There was no effect of treatment on location of symptoms. At
2 weeks, 11 (37%) participants in the treatment group and ﬁve
(17%) participants in the advice to remain active group reported
centralisation of the most distal leg pain; this difference was not
signiﬁcant (RR 2.2, 95% CI 0.9 to 5.6). At 4 weeks, 13 (43%)
participants in the treatment group and seven (23%) participants in
the advice to remain active group reported centralisation of the
most distal leg pain (RR 1.9, 95% CI 0.9 to 4.0), as presented in
Table 4. Individual participant data for all outcomes are presented
in Table 5 (see eAddenda for Table 5).
Discussion
This is the ﬁrst randomised, controlled trial of neurodynamic
treatment for chronic nerve-related leg pain. Adding neurody-
namic treatment to advice to remain active provided no additional
beneﬁt on the primary outcomes (ie, pain and disability 2 weeks
after randomisation). A signiﬁcant effect of treatment was found
for leg pain and low back pain at 4 weeks, function and global
perceived effect at 2 weeks and 4 weeks, but not for low back pain
at 2 weeks, and disability and location of symptoms at 2 and
4 weeks.
In two previous trials, patients treated with slump stretching
plus lumbar mobilisation and exercise achieved a signiﬁcant
Table 2
Unadjusted mean (SD) for continuous outcomes measured at baseline and at each follow-up time for each group, within-group unadjusted mean differences (SD), and
adjusted between-group differences (95% CI).
Outcome Groups Within-group difference Adjusted between-group differencea [26_TD$DIFF]




















Exp Con Exp Con Exp minus Con Exp minus Con
Leg pain (0 to 10)b[29_TD$DIFF] 6.1 (1.6) 6.1 (1.9) 4.1 (2.3) 5.1 (2.3) 3.7 (2.6) 6.1 (2.4) –1.9 (2.6) –1.0 (2.4) –2.3 (2.4) 0.1 (2.1) –1.1 (–2.3 to 0.1) –2.4 (–3.6 to –1.2)
Oswestry Disability
Index (0 to 100)
29 ( [30_TD$DIFF]8) 27 (15) 21 (12) 23 (12) 20 (12) 23 (12) –7.6 (13.7) –3.8 (9.4) –9.2 (15.3) –2.9 (8.2) –3.3 (–9.6 to 2.9) –5.0 (–11.0 to 1.1)
Low back pain
(0 to 10)b
5.5 (2.3) 5.1 (2.5) 4.2 (2.4) 4.9 (2.4) 4.2 (2.5) 5.4 (2.5) –1.1 (2.5) –0.1 (1.5) –1.3 (2.2) 0.4 (2.2) –0.9 (–2.2 to 0.3) –1.5 (–2.8 to –0.2)
PSFS (0 to 30) 14 (5.2) 15 (6.1) 20 (5.8) 15 (5.8) 19 (5.9) 15 (5.9) 6.3 (6.7) 0.7 (6.3) 5.6 (6.9) –0.1 (7.5) 5.2 (2.2 to 8.2) 4.7 (1.7 to 7.8)
Con= [32_TD$DIFF]Control group, [33_TD$DIFF]Exp= [34_TD$DIFF]Experimental group, PSFS=Patient [35_TD$DIFF]-Speciﬁc Functional Scale. Shaded cells =primary outcome.
a Adjusted for nerve root compromise [36_TD$DIFF].
b Average intensity during past 24hours [37_TD$DIFF].
Table 3
Unadjusted mean (SD) for global perceived effect at each assessment time for each group, and adjusted between-group difference (95% CI) at each assessment time.
Outcomes Groups Adjusted between-group differencea [31_TD$DIFF]
Week 2 Week 4 Week 2 Week 4
Exp (n=28) Con (n=28) Exp (n=27) Con (n=27) Exp minus Con Exp minus Con
Global perceived effect
(–5 to 5)
2.2 (1.2) –0.2 (2.1) 2.0 (1.5) –0.7 (1.9) 2.5 (1.6 to 3.5) 2.9 (1.9 to 3.9)
[31_TD$DIFF]Con= [32_TD$DIFF]Control group, [33_TD$DIFF]Exp= [34_TD$DIFF]Experimental group, PSFS=Patient [35_TD$DIFF]-Speciﬁc Functional Scale.
a Adjusted for nerve root compromise [38_TD$DIFF].
Table 4
Number of participants (%) in each group whose pain had centralised by each assessment point, and relative risk (95% CI) between groups.
Outcome Groups Relative risk between groups (95% CI)
Week 2 Week 4 Week 2 Week 4
Exp (n=30) Con (n=30) Exp (n=30) Con (n=30) Exp relative to Con Exp relative to Con
Pain centralised 11 (37) 5 (17) 13 (43) 7 (23) 2.2 (0.9 to 5.6) 1.9 (0.9 to 4.0)
[31_TD$DIFF]Con= [39_TD$DIFF]Control group, [33_TD$DIFF]Exp= [40_TD$DIFF]Experimental group.
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compared with mobilisation and exercise at 3 weeks.12,13 [69_TD$DIFF] Similar-
ly, a randomised trial involving participants with nerve-related
neck and arm pain found that adding neurodynamic treatment
improved pain and disability in the short-term, compared with
advice to remain active only.21 In contrast to those previous trials,
our trial found no signiﬁcant reduction in leg pain following
neurodynamic treatment at 2 weeks, and disability was largely
unaffected at all time points. Whereas those former studies
enrolled a mixed sample of [82_TD$DIFF] participants with acute, subacute and
chronic pain,2,13,21 [81_TD$DIFF] our trial recruited only individuals with
longstanding chronic leg pain. These contrasting results may
indicate that duration of symptoms may impact the effects of
neurodynamic treatment.
Following neurodynamic treatment, a progressive decrease in
leg pain was observed at each follow-up, reaching a reduction of
2.4 points at 4 weeks. Conversely, participants [83_TD$DIFF]allocated to
the advice to remain active group improved 1 point at 2 weeks,
but returned to baseline levels of leg pain at 4 weeks. The
observed difference in leg pain behaviour along the study
period may indicate that neurodynamic treatment altered the
natural history of leg pain in the short [84_TD$DIFF] term. Whilst recent
evidence shows that only a small proportion of patients with
chronic low back pain have ﬂuctuating symptoms,28 it is
currently unknown whether this ﬁnding also applies to the
course of leg pain.
It has been suggested that participants with neuropathic pain
or nerve root compromise would not beneﬁt from neurodynamic
treatment, and that treatment effects would be diluted in trials
with more relaxed inclusion criteria.5,21 Scha¨fer et al5 proposed
a mutually exclusive classiﬁcation system to overcome theinappropriateness of one-size-ﬁts-all approaches of treatment
for nerve-related leg pain. In this classiﬁcation system, only
patients presenting signs of nerve mechanosensitivity without
nerve root compromise and neuropathic pain features would
beneﬁt from neurodynamic treatment. In our trial, participants
with both neuropathic pain features and nerve root compromise
were included and yet signiﬁcant treatment effects were noted
for some secondary outcomes. Although these ﬁndings may
challenge current understanding of which clinical character-
istics would increase the likelihood of achieving better out-
comes with neurodynamic treatment, caution is needed when
interpreting these results. For instance, signiﬁcant effects of
treatment were only noted for secondary outcomes, and the
conﬁdence interval around the estimate of treatment effect on
function was quite imprecise. Future studies with rigorous pre-
planned subgroup [86_TD$DIFF]analyses29 [85_TD$DIFF] and adequate sample size to
conduct such [86_TD$DIFF]analyses should clarify whether the presence (or
absence) of neuropathic pain and nerve root compromise are
treatment-effect modiﬁers for patients receiving neurodynamic
treatment.
The strengths of this trial were the implementation of true
randomisation, allocation concealment, blinding of outcome
assessors, and intention-to-treat analysis, which helped to
preserve internal validity and reduce the likelihood of bias.15
Furthermore, the broad inclusion criteria increased the generali-
sability of the ﬁndings.
Some limitations must be highlighted. As this trial only
assessed short-term outcomes, it is currently unknown whether
the results would be sustained for the long term. Wide 95%
conﬁdence intervals indicate some imprecision in the estimates of
the effect of neurodynamic treatment on some outcomes,
Ferreira et al: Neurodynamic treatment for nerve-related leg pain202particularly disability and function. Moreover, participants in the
experimental group were seen by the therapist four times during
the treatment period, while participants in the control group had
face-to-face contact with the study staff only once. The between-
group difference in the quantity of visits may have created
attention bias, which may explain why participants in the control
group improved in some outcomesmeasures at the ﬁrst follow-up,
but returned to the baseline level at the 4-week follow-up. Apart
from attention bias, placebo effects might explain some degree of
the observed treatment effects. Participants receiving neurody-
namic treatment were exposed to a therapeutic context, in which
the interactionwith the therapist aswell as to a therapeutic setting
may have potentiated improvement, comparedwith thosewho did
not receive treatment.30 Since, to date, there is no validated sham
neurodynamic treatment for conditions of the lower quadrant, the
true therapeutic effect of this approach needs to be determined by
future placebo-controlled studies.31
In conclusion, when added to advice to remain active,
neurodynamic treatment was not capable of reducing leg pain
and disability. Based on the ﬁndings of the primary outcomes,
neurodynamic treatment should not be recommended for the
treatment of chronic nerve-related leg pain. However, given the
beneﬁcial effects on several secondary outcomes, trials with larger
samples and longer follow-up assessments should be conducted in
order to determine the extent to which the results of these
secondary outcomes are relevant to patients with chronic nerve-
related leg pain.What is already known on this topic: Radiating leg pain is
prevalent among people with low back pain. Neurodynamic
treatment (active and passive movements in specific positions
tomobilise nervous systemstructures) has not been adequate-
ly assessed as a potential therapy for radiating leg pain.
What this study adds: Adding neurodynamic treatment to
advice to remain active did not improve leg pain and disability
at the end of the 2-week intervention period, although function
and perceived global effect had significantly improved. Two
weeks after the intervention period, leg pain, low back pain,
function and global perceived effect were all significantly
better when neurodynamic treatment was added to advice
to remain active.eAddenda: Table 5 and Appendix 1 (video) can be found online
at doi:10.1016/j.jphys.2016.08.007
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